Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
S Sloan
Observed names:
S. S. Sloan,
S. SLOAN,
S. Sloan
Institution:
Abivax (France)
Observed institutions:
University of Nevada, Reno,
University of California, Irvine,
Oklahoma Foundation for Digestive Research,
Abivax (France),
Janssen Scientific Affairs (United States),
Janssen Research & Development (United States),
Rush University
show all 7
OpenAlex ID:
A5113583910
Impaired egress rather than increased access: an important independent predictor of erosive oesophagitis
2002
·
M. P. Jones
, S. S. Sloan
, et al.
·
Neurogastroenterology & Motility
·
72
Meal‐stimulated gastric acid secretion and integrated gastric acidity in gastro‐oesophageal reflux disease
2003
·
J. D. Gardner
, S. Sloan
, et al.
·
Alimentary Pharmacology & Therapeutics
·
40
PDF
Integrated acidity and rabeprazole pharmacology
2002
·
J. D. Gardner
, C. Perdomo
, et al.
·
Alimentary Pharmacology & Therapeutics
·
37
The basis for the decreased response to proton pump inhibitors in gastro‐oesophageal reflux disease patients without erosive oesophagitis
2003
·
J. D. Gardner
, H. Gallo‐Torres
, et al.
·
Alimentary Pharmacology & Therapeutics
·
29
A national inpatient cost estimate of percutaneous endoscopic gastrostomy (PEG)-associated aspiration pneumonia.
2000
·
R Siddique
, C A Neslusan
, et al.
·
PubMed
·
29
Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro‐oesophageal reflux disease treated with a proton pump inhibitor
2003
·
J. D. Gardner
, S. Sloan
, et al.
·
Alimentary Pharmacology & Therapeutics
·
20
P649 Comparison of the KU Leuven ustekinumab concentration assay and the antibodies-to-ustekinumab assay with assays developed at Janssen R&D and used in clinical studies of IBD patients
2018
·
J C Marini
, A Gils
, et al.
·
Journal of Crohn s and Colitis
·
15
DOP10 Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy
2020
·
T Kucharzik
, R Wilkens
, et al.
·
Journal of Crohn s and Colitis
·
14
PDF
Oesophageal pH has a power‐law distribution in control and gastro‐oesophageal reflux disease subjects
2004
·
J. D. Gardner
, S. Sloan
, et al.
·
Alimentary Pharmacology & Therapeutics
·
14
PDF
The role of age and salivation in acid clearance in symptomatic patients with gastro‐oesophageal reflux disease
2001
·
W. C. Orr
, C.‐L. Chen
, et al.
·
Alimentary Pharmacology & Therapeutics
·
14
Frequency analyses of gastric pH in control and gastro‐oesophageal reflux disease subjects treated with a proton‐pump inhibitor
2004
·
J. D. Gardner
, S. Sloan
, et al.
·
Alimentary Pharmacology & Therapeutics
·
12
PDF
DOP54 Efficacy and safety of ustekinumab through Week 16 in patients with moderate-to-severe ulcerative colitis randomised to ustekinumab: results from the UNIFI induction trial
2019
·
S Danese
, B E Sands
, et al.
·
Journal of Crohn s and Colitis
·
9
The fractal nature of human gastro‐oesophageal reflux
2005
·
J. D. GARDNER
, W. YOUNG
, et al.
·
Alimentary Pharmacology & Therapeutics
·
9
PDF
Indirect Treatment Comparison of Ustekinumab Versus Other Biologics In Moderate To Severe Crohn’s Disease: A 1-Year Treatment Sequence Analysis
2016
·
M Pacou
, L Mesana
, et al.
·
Value in Health
·
8
PDF
Intestinal ultrasound response and transmural healing after ustekinumab induction in Crohn’s disease: Week 16 interim analysis of the STARDUST trial substudy
2020
·
T Kucharzik
, R Wilkens
, et al.
·
Zeitschrift für Gastroenterologie
·
7
DOP13 Clinical and endoscopic response to ustekinumab in Crohn’s disease: Week 16 interim analysis of the STARDUST trial
2020
·
S Danese
, S Vermeire
, et al.
·
Journal of Crohn s and Colitis
·
7
PDF
The effects of changing temperature correction factors on measures of acidity calculated from gastric and oesophageal pH recordings
2006
·
J. D. GARDNER
, W. YOUNG
, et al.
·
Alimentary Pharmacology & Therapeutics
·
7
PDF
Heartburn severity can predict pathologic oesophageal reflux in gastro‐oesophageal reflux disease patients treated with a proton‐pump inhibitor
2003
·
J. D. Gardner
, S. Sloan
, et al.
·
Alimentary Pharmacology & Therapeutics
·
6
PDF
Hiatal hernia (HH) size is the principal determinant of esophagitis in patients with symptomatic gastroesophageal reflux disease
1998
·
M.P. Jones
, S. Sloan
, et al.
·
Gastroenterology
·
6
PDF
Significant heartburn relief after the first dose of rabeprazole sodium in non-erosive reflux disease (NERD) patients
2000
·
P. Miner
, S. Sloan
, et al.
·
Gastroenterology
·
3
PDF
P985 Efficacy and safety of de-escalation from 50 mg to 25 mg of oral, once-daily, obefazimod for the third and fifth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): An interim analysis
2024
·
P Dulai
, B E Sands
, et al.
·
Journal of Crohn s and Colitis
·
2
PDF
DOP12 Efficacy and safety of obefazimod in UC patients at weeks 48 and 96 of an open-label maintenance study among clinical responders at week 8 of the Phase 2b induction trial
2024
·
S Vermeire
, L Peyrin-Biroulet
, et al.
·
Journal of Crohn s and Colitis
·
2
PDF
A147 Response and Remission After 16 Weeks of Ustekinumab– an All Patients Analysis From the Uniti Crohn’s Studies
2018
·
J F Colombel
, S Sloan
, et al.
·
Journal of the Canadian Association of Gastroenterology
·
2
PDF
P281 Combined clinical and biological response (concomitant CRP and faecal calprotectin reductions) in induction and maintenance from the phase 3 ustekinumab Crohn’s disease studies
2018
·
J -F Colombel
, C Gasink
, et al.
·
Journal of Crohn s and Colitis
·
2
P186 Outcomes of maintenance ustekinumab therapy for Crohn’s disease based on inflammatory burden: A post-hoc analysis of the UNITI trials
2018
·
S Ghosh
, B Sattin
, et al.
·
Journal of Crohn s and Colitis
·
2
Show more works
View as search
Works count:
39
Citation count:
373
H-index:
11
I10-index:
11
Year
Topic
Type